Estrella Immunopharma, Inc. (NASDAQ:ESLA) Stock Short Interest Jumps 180.2%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 599,647 shares, a growth of 180.2% from the September 30th total of 214,030 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily trading volume, of 7,569,648 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Down 12.3%

Shares of ESLA stock opened at $0.64 on Friday. Estrella Immunopharma has a one year low of $0.24 and a one year high of $3.15. The company has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.98.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04. Equities analysts predict that Estrella Immunopharma will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On Estrella Immunopharma

A hedge fund recently bought a new stake in Estrella Immunopharma stock. BlackRock Inc. purchased a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells.

Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.

Estrella became a publicly traded company through a business combination with TradeUP Global Corporation.